MCL in 2026: Where are we now and how does the future look for MCL treatment?

You can now see the webbinar from MCL in 2026: Where are we now and how does the future look for MCL treatment? (Mantle Cell Lymphoma)

The webinar discusses current and future strategies for treating mantle cell lymphoma, with a focus on reducing reliance on traditional chemotherapy. Results from key studies such as ENRICH and TRIANGLE are presented to support the early use of BTK inhibitors. Chemotherapy-free combinations demonstrate good efficacy for elderly patients, while younger patients may potentially avoid autologous stem cell transplantation. In the relapsed setting, new alternatives like pirtobrutinib, BCL2 inhibitors, and CAR T-cell therapy are highlighted as important tools. The conclusion emphasizes that optimized first-line treatment is crucial for long-term patient survival.

(this summary is AI generated and not proofread, scroll down for a full transcript of the webinar)

Program*

• MCL in 2026: Where are we now and how does the future look for MCL treatment 2026 - Dr Toby A. Eyre
• Discussions from a Swedish perspective - Ingrid Glimelius and Mats Jerkeman

Thanks to:

Organizer:

Relevant keywords: Mantle cell lymphoma (MCL), BTK inhibitors, TRIANGLE study, CAR-T, BCL2 inhibitors, Pirtobrutinib